Bibliography
- FOLKMAN J: Tumor angiogenesis: therapeutic implica-tions. New Engl. J. Med. (1971) 285:1182–1186.
- FOLKMAN J: Angiogenesis in cancer, vascular, rheuma-toid and other disease. Nature Med. (1995) 1:27–31.
- ••A very good and timely review of the whole area of angio-genesis in disease.
- ZARDI L, CARNEMOLLA B, TORBES AS et al.: Trans- formed human cells produce a new fibronectin iso-form by preferential alternative splicing of a previously unobserved exon. EMBO 1 (1987) 6:2337–2342.
- CARNEMOLLA B, LEPRINI A, ALLEMANI G etal. The inclu- sion of the Type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J. Biol. Chem. (1992) 24:24689–24692.
- WINTER G, HOOGENBOOM HR, GRIFFITHS A et al.: Mak- ing antibodies by phage display technology. Ann. Rev. Immunol. (1994) 12:433–455.
- ••One of the best all-round reviews on the phage antibodytechnology.
- CARNEMOLLA B, NERI D, CASTELLANI P et al: Phage anti-bodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer (1996) 68:397–405.
- NISSIM A, HOOGENBOOM HR, TOMLINSON IM et al.: An-tibody fragments from a 'single pot' phage display li-brary as immunochemical reagents. EMBO 1 (1994) 13: 692.
- NERI D, CARNEMOLLA B, NISSIM A et al.: Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Na-ture Biotechnol (1998) 15:1271–1275.
- •A good research paper describing the use of the anti-ED-B antibodies with some impressive, real time fluorescent im-aging data.
- BEGENT RHJ, VERHAAR MJ, CHESTER KA et al.: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial li-brary. Nature Med. (1996) 2:979–984.
- •The first clinical example of the use of a scFv, with promis-ing results.
- OLSON TA, MOHANRAJ D, ROY S et al.: Targeting the tu- mor vasculature: inhibition of tumor growth by a vas-cular endothelial growth factor-toxin conjugate. Int. J. Cancer (1997) 73:865–870.
- ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treat- ment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279:377–380.
- •This paper and references cited within show an ingenious approach of peptide selection and targeting.
- BURROWS FJ, THORPE PE: Eradication of large solid tu-mors in mice with an immunotoxin directed against tumor vasculature. PNAS (USA) (1993) 90:8996–9000.
- SEON BK, MATSUNO F, HARUTA Y et al: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vascula-ture with antihuman endoglin immunotoxin. Clin. Cancer Res. (1997) 3:1031–1044.
- O'REILLY MS, HOLMGREN L, CHEN C et al.: Angiostatin induces and sustains dormancy of human primary tu-mors in mice. Nature Merl. (1996) 2:689–692.